Disease Indications Articles
Researchers have developed an experimental therapeutic nasal DNA vaccine for tuberculosis.
Scientists have developed a new HIV vaccine that has the potential to protect humans from developing HIV infection and AIDS.
The Bacillus Calmette-Guérin accine may alter immune activity around the brain and change levels of a protein closely associated with Alzheimer’s disease in older adults without evidence of the condition.
The U.S. Food and Drug Administration has approved veligrotug-vvze (Lumvoa; Viridian Therapeutics) to treat thyroid eye disease.
According to a cohort study using target trial emulation, older adults at higher risk for dementia are less likely to have a dementia diagnosis if they received a herpes zoster (shingles) vaccine.
A study has found that intravenous immune globulin (IVIG) reduces grade 2 infections by 67 percent in patients with chronic lymphocytic leukemia.
Researchers have found that adults 65 and older who received a high-dose influenza vaccine had a significantly lower risk of developing Alzheimer’s disease compared to those who received the standard dose.
A recent study has found intravenous immune globulin (IVIG) therapy in infants with hemolytic disease of the fetus and newborn (HDFN) found that it could be beneficial.
According to a recent study, adding intravenous methylprednisolone to intravenous immune globulin induction therapy does not significantly increase remission rates among patients with chronic inflammatory demyelinating polyradiculoneuropathy.
The U.S. Food and Drug Administration has granted a designation as breakthrough therapy to Wayrilz (rilzabrutinib), a novel oral, reversible Bruton’s tyrosine kinase inhibitor, for the treatment of patients with warm autoimmune hemolytic anemia.
FDA has granted fast track designation to gamgertamig (OM336) for the treatment of immune thrombocytopenia and cold and warm autoimmune hemolytic anemia.
According to a study that analyzed the Veteran’s Health Administration records found there is no evidence to suggest COVID-19 vaccination increases the risk of developing idiopathic inflammatory myositis.